Focal Neuroendocrine Differentiation of Conventional Prostate Adenocarcinoma as a Prognostic Factor after Radical Prostatectomy: A Systematic Review and Meta-Analysis.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
19 Mar 2019
Historique:
received: 02 02 2019
revised: 11 03 2019
accepted: 13 03 2019
entrez: 22 3 2019
pubmed: 22 3 2019
medline: 11 7 2019
Statut: epublish

Résumé

The biologic and prognostic value of focal neuroendocrine differentiation (NED) in conventional prostate adenocarcinoma (PC) patients who undergo radical prostatectomy (RP) remains controversial. In this systematic review and meta-analysis, we assessed the association of focal NED in conventional PC with oncological outcomes after RP. A literature search using PubMed, Scopus, Web of Science, and Cochrane Library was conducted on December 2018 to find relevant studies according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines. We used a fixed-effect model to analyze the impact of focal NED in RP specimen on progression-free survival defined by biochemical recurrence (BCR). A total of 16 studies with the outcomes of disease progression and survival were eligible. No patient in these studies received androgen deprivation therapy prior to RP. Eleven studies found no significant correlation between focal NED and outcomes of interest, while five studies reported a significant association of focal NED assessed by immunohistochemical chromogranin A or serotonin staining with BCR or survival. Focal NED was associated with higher BCR rates after RP with a pooled HR of 1.39 (95% CI 1.07‒1.81) in five studies. No heterogeneity was reported in this analysis (I² = 21.7%,

Identifiants

pubmed: 30893781
pii: ijms20061374
doi: 10.3390/ijms20061374
pmc: PMC6471399
pii:
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Références

Urology. 2000 May;55(5):743-9
pubmed: 10792093
Urology. 2000 Dec 20;56(6):1011-5
pubmed: 11113749
Prostate. 2001 Jun 15;48(1):7-15
pubmed: 11391682
J Urol. 2002 Sep;168(3):1204-11
pubmed: 12187268
J Urol. 2004 Mar;171(3):1089-92
pubmed: 14767277
Cancer. 2004 Feb 15;100(4):751-7
pubmed: 14770431
J Clin Oncol. 2004 May 1;22(9):1655-63
pubmed: 15117988
JAMA. 2005 Jul 27;294(4):433-9
pubmed: 16046649
BJU Int. 2006 Aug;98(2):329-34
pubmed: 16879673
J Clin Oncol. 2007 Feb 1;25(4):349-55
pubmed: 17264329
Anticancer Res. 2007 Sep-Oct;27(5B):3651-60
pubmed: 17972531
World J Urol. 2008 Jun;26(3):243-50
pubmed: 18392627
Prostate. 2008 Dec 1;68(16):1806-15
pubmed: 18767028
Pathobiology. 2009;76(1):30-8
pubmed: 19188748
BJU Int. 2009 Jun;103(11):1464-70
pubmed: 19254281
J Urol. 2010 Sep;184(3):1182-8
pubmed: 20663522
Eur Urol. 2010 Nov;58(5):687-700
pubmed: 20727668
Prostate. 2011 Dec;71(16):1752-8
pubmed: 21480309
Acta Oncol. 2011 Jun;50 Suppl 1:61-75
pubmed: 21604943
Eur Urol. 2013 Nov;64(5):786-98
pubmed: 23664423
Am J Surg Pathol. 2014 Jun;38(6):756-67
pubmed: 24705311
Front Oncol. 2014 Mar 25;4:60
pubmed: 24724054
J Clin Oncol. 2014 Oct 20;32(30):3383-90
pubmed: 25225419
Urol Oncol. 2015 Jun;33(6):265.e1-7
pubmed: 25238700
Am J Clin Exp Urol. 2014 Dec 09;2(4):273-85
pubmed: 25606573
BJU Int. 2017 Feb;119(2):234-238
pubmed: 26940243
Eur Urol. 2017 Apr;71(4):618-629
pubmed: 27568654
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
Pathol Oncol Res. 2017 Jul;23(3):643-650
pubmed: 28012116
Int J Mol Sci. 2017 Jul 28;18(8):null
pubmed: 28788048
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Cold Spring Harb Perspect Med. 2019 Feb 1;9(2):null
pubmed: 29844220
Int J Cancer. 1995 Jul 28;62(3):252-8
pubmed: 7543077
Cancer. 1994 Oct 1;74(7):1899-903
pubmed: 8082095
J Pathol. 1996 Apr;178(4):437-41
pubmed: 8691323
Hum Pathol. 1996 Jul;27(7):683-7
pubmed: 8698312
Cancer. 1997 Dec 1;80(11):2109-19
pubmed: 9392333
Prostate Suppl. 1998;8:37-42
pubmed: 9690662

Auteurs

Mehdi Kardoust Parizi (M)

Department of Urology, Medical University of Vienna, A-1090 Vienna, Austria. m.kardoust@yahoo.com.
Department of Urology, Shariati Hospital, Tehran University of Medical Sciences, Teheran 1411713135, Iran. m.kardoust@yahoo.com.

Takehiro Iwata (T)

Department of Urology, Medical University of Vienna, A-1090 Vienna, Austria. takehiroiwata1221@gmail.com.
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan. takehiroiwata1221@gmail.com.

Shoji Kimura (S)

Department of Urology, Medical University of Vienna, A-1090 Vienna, Austria. shoji.kimura-1228@hotmail.co.jp.
Department of Urology, Jikei University School of Medicine, Tokyo 105-8461, Japan. shoji.kimura-1228@hotmail.co.jp.

Florian Janisch (F)

Department of Urology, Medical University of Vienna, A-1090 Vienna, Austria. drfjanisch@gmail.com.
Department of Urology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany. drfjanisch@gmail.com.

Mohammad Abufaraj (M)

Department of Urology, Medical University of Vienna, A-1090 Vienna, Austria. dr.abufaraj@gmail.com.
Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman 11942, Jordan. dr.abufaraj@gmail.com.

Pierre I Karakiewicz (PI)

Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC H3h 1s8, Canada. pierre.karakiewicz@umontreal.ca.
Centre de recherche du Centre Hospitalier de l'Université de Montréal (CR-CHUM), Institut du Cancer de Montréal, Montréal, QC H3h 1s8, Canada. pierre.karakiewicz@umontreal.ca.

Dmitry Enikeev (D)

Institute for Urology and Reproductive Health, Sechenov University, Moscow 119991, Russia. dvenikeev@gmail.com.

Leonid M Rapoport (LM)

Institute for Urology and Reproductive Health, Sechenov University, Moscow 119991, Russia. urologystatement1@yandex.com.

Georg Hutterer (G)

Department of Urology, Medical University Graz, A-8036 Graz, Austria. g.hutterer@gmail.com.

Shahrokh F Shariat (SF)

Institute for Urology and Reproductive Health, Sechenov University, Moscow 119991, Russia. sfshariat@gmail.com.
Department of Urology, Weill Cornell Medical College, New York, NY 10011, USA. sfshariat@gmail.com.
Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. sfshariat@gmail.com.
Karl Landsteiner Institute of Urology and Andrology, A-1090 Vienna, Austria. sfshariat@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH